Studies have shown that inhibition of CCL2 reduces bone marrow monocyte infiltration and TAM polarization, thereby slowing down tumor growth in various cancers, such as lung cancer, bladder cancer, and hepatocellular carcinoma (HCC) [83]. This evidence concerns the gene CCL2 and hepatocellular carcinoma.